Showing 1 - 14 results of 14 for search 'Matthew J. Maurer', query time: 0.21s Refine Results
  1. 1
    Degradation Signals for Ubiquitin-Proteasome Dependent Cytosolic Protein Quality Control (CytoQC) in Yeast

    Degradation Signals for Ubiquitin-Proteasome Dependent Cytosolic Protein Quality Control (CytoQC) in Yeast by Matthew J. Maurer, Eric D. Spear, Allen T. Yu, Evan J. Lee, Saba Shahzad, Susan Michaelis

    Published 2016-07-01
    Get full text
    Article
  2. 2
    JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis

    JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis by Kang Le, Linda E. Wellik, Matthew J. Maurer, Ellen D. McPhail, Thomas E. Witzig, Mamta Gupta

    Published 2021-03-01
    Get full text
    Article
  3. 3
    Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.

    Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A. by Diogo Torres, Xiaonan Hou, Laurie Bale, Ethan P Heinzen, Matthew J Maurer, Valentina Zanfagnin, Ann L Oberg, Cheryl Conover, S John Weroha

    Published 2019-01-01
    Get full text
    Article
  4. 4
    Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials

    Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials by Yucai Wang, Shouhao Zhou, Xinyue Qi, Fang Yang, Matthew J. Maurer, Thomas M. Habermann, Thomas E. Witzig, Michael L. Wang, Grzegorz S. Nowakowski

    Published 2022-01-01
    Get full text
    Article
  5. 5
    The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

    The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. by Claudia C Preston, Matthew J Maurer, Ann L Oberg, Daniel W Visscher, Kimberly R Kalli, Lynn C Hartmann, Ellen L Goode, Keith L Knutson

    Published 2013-01-01
    Get full text
    Article
  6. 6
    Selection of chromosomal DNA libraries using a multiplex CRISPR system

    Selection of chromosomal DNA libraries using a multiplex CRISPR system by Owen W Ryan, Jeffrey M Skerker, Matthew J Maurer, Xin Li, Jordan C Tsai, Snigdha Poddar, Michael E Lee, Will DeLoache, John E Dueber, Adam P Arkin, Jamie HD Cate

    Published 2014-08-01
    Get full text
    Article
  7. 7
    Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era

    Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era by Arushi Khurana, Raphael Mwangi, Stephen M. Ansell, Thomas M. Habermann, James R. Cerhan, Christopher Strouse, Brian K. Link, Yucai Wang, Rebecca L. King, William R. Macon, J. C. Villasboas, Thomas E. Witzig, Matthew J. Maurer, Grzegorz S. Nowakowski

    Published 2021-07-01
    Get full text
    Article
  8. 8
    Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era

    Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era by Cristina Correia, Matthew J. Maurer, Samantha J. McDonough, Paula A. Schneider, Paige E. Ross, Anne J. Novak, Andrew L. Feldman, James R. Cerhan, Susan L. Slager, Thomas E. Witzig, Bruce W. Eckloff, Hu Li, Grzegorz S. Nowakowski, Scott H. Kaufmann

    Published 2023-05-01
    Get full text
    Article
  9. 9
    Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting

    Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting by Ann L. Oberg, Ethan P. Heinzen, Xiaonan Hou, Mariam M. Al Hilli, Rachel M. Hurley, Andrea E. Wahner Hendrickson, Krista M. Goergen, Melissa C. Larson, Marc A. Becker, Jeanette E. Eckel-Passow, Matthew J. Maurer, Scott H. Kaufmann, Paul Haluska, S. John Weroha

    Published 2021-04-01
    Get full text
    Article
  10. 10
    Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria

    Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria by Rebecca L. King, Arushi Khurana, Raphael Mwangi, Angelo Fama, Kay M. Ristow, Matthew J. Maurer, William R. Macon, Stephen M. Ansell, N. Nora Bennani, Yogish C. Kudva, Randall C. Walker, Kymberly D. Watt, Thomas R. Schwab, Sudhir S. Kushwaha, James R. Cerhan, Thomas M. Habermann

    Published 2021-10-01
    Get full text
    Article
  11. 11
    T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma

    T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma by Zhi-Zhang Yang, Hyo Jin Kim, Hongyan Wu, Xinyi Tang, Yue Yu, Jordan Krull, Daniel P. Larson, Raymond M. Moore, Matthew J. Maurer, Kevin D. Pavelko, Shahrzad Jalali, Joshua C. Pritchett, Rekha Mudappathi, Junwen Wang, Jose C. Villasboas, Patrizia Mondello, Anne J. Novak, Stephen M. Ansell

    Published 2023-08-01
    Get full text
    Article
  12. 12
    Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

    Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study by Allison M. Bock, Jennifer J. Gile, Melissa C. Larson, Kittika Poonsombudlert, Reema K. Tawfiq, Seth Maliske, Matthew J. Maurer, Brian F. Kabat, Jonas Paludo, David J. Inwards, Sabarish Ayyappan, Brian K. Link, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, James R. Cerhan, Umar Farooq, Yucai Wang

    Published 2023-11-01
    Get full text
    Article
  13. 13
    CHFR and Paclitaxel Sensitivity of Ovarian Cancer

    CHFR and Paclitaxel Sensitivity of Ovarian Cancer by Andrea E. Wahner Hendrickson, Daniel W. Visscher, Xiaonan Hou, Krista M. Goergen, Hunter J. Atkinson, Thomas G. Beito, Vivian Negron, Wilma L. Lingle, Amy K. Bruzek, Rachel M. Hurley, Jill M. Wagner, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Melissa C. Larson, Matthew J. Maurer, Kimberly R. Kalli, Ann L. Oberg, S. John Weroha, Scott H. Kaufmann

    Published 2021-11-01
    Get full text
    Article
  14. 14
    Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatmentResearch in context

    Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatmentResearch in context by Luca Arcaini, Côme Bommier, Juan Pablo Alderuccio, Michele Merli, Nicole Fabbri, Maria Elena Nizzoli, Matthew J. Maurer, Vittoria Tarantino, Simone Ferrero, Sara Rattotti, Annalisa Talami, Roberta Murru, Arushi Khurana, Raphael Mwangi, Marina Deodato, Emanuele Cencini, Francesca Re, Carlo Visco, Andrew L. Feldman, Brian K. Link, Marcia Torresan Delamain, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés J.M. Ferreri, Caterina Cecilia Stelitano, Elsa Pennese, Thomas M. Habermann, Luigi Marcheselli, Sunwoo Han, Isildinha M. Reis, Marco Paulli, Izidore S. Lossos, James R. Cerhan, Stefano Luminari

    Published 2024-06-01
    Get full text
    Article

Search Tools: